Article Sidebar
Views pdf: 48
COST-UTILITY ANALYSIS OF EMPAGLIFLOZIN IN TREATMENT FOR TYPE-2 DIABETES MELLITUS IN VIETNAM
Main Article Content
Abstract
Objective: To evaluate the cost-effectiveness of Empagliflozin in the treatment of type 2 diabetes mellitus in Vietnam. Methodology: A model based cost-utility analysis was performed applying the payer perspective. The Markov model with 5 states was built to simulate the natural history of type 2 diabetes mellitus over a lifetime horizon with 1-year cycle length. The parameters of cost, clinical efficacy, quality of life are collected from published literature sources. Results: Empagliflozin had a higher cost of treatment than standard treatment regimens (SoCs), and also had a higher number of quality adjusted life year (QALY). The basecase analysis results show that the ICER value is VND 45,825,181 per 1 QALY gained. One-way and probabilistic sensitivity analysis provides the certainty about the cost-effective outcome of Empagliflozin. Conclusion: Empagliflozin is cost-effective in treating type 2 diabetes in Vietnam.
Article Details
Keywords
diabetes mellitus, type 2, cost – effectiveness, Empagliflozin
References
2. Pham, N.M. and K. Eggleston, Diabetes prevalence and risk factors among vietnamese adults: findings from community-based screening programs. Diabetes Care, 2015. 38(5): p. e77-8.
3. Tuan Kiet Pham, H., et al., Direct medical costs of diabetes and its complications in Vietnam: A national health insurance database study. Diabetes Res Clin Pract, 2020: p. 108051.
4. Zoungas, S., et al., Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care, 2009. 32(11): p. 2068-74.
5. McGuire, D.K., et al., Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol, 2020. 8(12): p. 949-959.
6. Inzucchi, S.E., et al., Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. Diabetes Care, 2019. 42(4): p. e53-e55.
7. Zinman, B., et al., Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med, 2015. 373(22): p. 2117-28.
8. Kiều Thị Tuyết Mai, Phân tích chi phí - hiệu quả của một số phác đồ điều trị Đái tháo đường típ 2 tại Việt Nam. 2021, Trường Đại học Dược Hà Nội: Hà Nội.
9. U.K. Prospective Diabetes Study Group, Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). . Diabetes Care, 1999. 22(7): p. 1125-36.